Publication | Open Access

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

VaccinationVaccine SafetyVaccinologyInterim AnalysisVaccine DevelopmentControlled Phase 3ImmunologyVaccine TestingVirologyVaccine EfficacyMedicineVaccine ResearchCovid-19